NCT06824701 2026-04-06
TARZAN
University of Utah
Phase 1 Suspended
Clinical Trials
8 trialsNCT07502872 2026-03-31
TPG
Brown University
Phase 2 Not yet recruiting
NCT06213311 2026-01-14
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT02992522 2025-09-09
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT04578600 2025-04-24
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
University of California, Davis
Phase 1 Completed
NCT05968001 2023-08-01
Obinutuzumab in Chinese Real-world Patients With iNHL
Affiliated Hospital of Nantong University
Not yet recruiting
NCT05797948 2023-04-04
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University
Phase NA Unknown
NCT02670317 2017-03-20
FIL-GALILEO
Fondazione Italiana Linfomi - ETS
Phase 2 Terminated